Hot Features
Premium
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Amicus Therapeutics Inc | FOLD | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 9.72 | 03:00:08 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 9.72 |
| Trades | Shares Traded | Average Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 9.02 - 14.57 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| - | 0 | US$ 9.72 | USD |
Amicus Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 2.87B | 295.38M | - | 399.36M | -151.58M | -0.51 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Amicus Therapeutics News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical FOLD Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 9.61 | 10.06 | 9.28 | 9.68 | 2,202,484 | 0.11 | 1.14% |
| 1 Month | 10.40 | 10.79 | 9.02 | 9.84 | 2,712,000 | -0.68 | -6.54% |
| 3 Months | 13.15 | 13.595 | 9.02 | 11.08 | 2,935,830 | -3.43 | -26.08% |
| 6 Months | 10.64 | 14.57 | 9.02 | 12.03 | 3,063,170 | -0.92 | -8.65% |
| 1 Year | 11.81 | 14.57 | 9.02 | 12.10 | 2,731,461 | -2.09 | -17.70% |
| 3 Years | 9.01 | 14.57 | 5.91 | 10.93 | 2,714,236 | 0.71 | 7.88% |
| 5 Years | 11.74 | 25.39 | 5.91 | 11.55 | 2,744,640 | -2.02 | -17.21% |
Amicus Therapeutics Description
| Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. |
